Live Breaking News & Updates on Global Health Sciences Wellness Strategy

10:00 – 11:00 am
2020 was a year like no other as the annual biopharma M&A total fell to the lowest level since EY began publishing its annual M&A Firepower report in 2013. In the first half of the year, the specter of COVID-19 deterred deals; as economies started to reopen, persistently high valuations were another reason many buyers remained on the fence. In the midst of such uncertainty, an innovation narrative emerged, with growing evidence of the power of new technologies, from antibody drug conjugates in oncology to RNA-based vaccines. These new innovations sparked many of 2020’s most notable deals and are sure to be important in the future. In this one hour panel discussion, we will discuss the current state of biopharma dealmaking and its implications for 2021 with M&A leaders from across the industry. ....

David Rhew , Stefan Oschmann , Peter Behner , Joseph Devivo , Piper Sandler , Susan Morano , John Babitt , Orlando Serani , Brian Malkin , John Young , Christopher Cleary , Janssen Pharmaceutical Companies Of Johnson , Merck Kga , Health Systems , Bristol Myers Squibb , Medtech Panel , Global Health Sciences Wellness Strategy , Corporate Development , Merck Kgaa , Ernst Young , Life Sciences , Program Architect Advanced Cell Therapies Supply Chain , Business Development , Global Group Head , Group President , Chief Business Officer ,